Minirin Melt (Desmopressin)

Desmopressin is a synthetic analogue of the hormone vasopressin. It selectively activates V2 receptors in the kidney’s collecting ducts, which raises intracellular cAMP and promotes insertion of aquaporin‑2 channels, allowing more water to be reabsorbed. In the vascular endothelium, V2 activation increases release of factor VIII and von Willebrand factor, aiding blood clot formation.

The dose of Minirin Melt is individualized and set by the prescribing clinician based on the patient’s condition, age, renal function, and response to therapy. Dosage may be adjusted during treatment, and patients should follow the specific instructions provided by their healthcare professional.

Safety of desmopressin during pregnancy and lactation has not been definitively established. The drug should be used only if the potential benefit justifies any possible risk to the fetus or infant. Physicians will evaluate the clinical situation and discuss potential risks with the patient before prescribing.

To order Minirin Melt, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, confirming trade or institutional credentials before providing a formal quotation that includes pricing, availability, shipping details and any necessary import documentation.

Minirin Melt (desmopressin) offers a longer duration of action and a more convenient oral melt formulation compared with intranasal desmopressin sprays or injectable vasopressin. It provides a selective V2‑receptor effect, reducing the risk of vasoconstriction seen with non‑selective vasopressin analogues, while maintaining efficacy for water balance and hemostasis.

Minirin Melt should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in their original blister pack, protect them from moisture and direct sunlight, and avoid storing them in high‑humidity environments such as bathrooms.

Minirin Melt is taken orally. The tablet is placed on the tongue and allowed to melt completely without chewing or drinking water for a few minutes. After the tablet has dissolved, the patient may swallow any remaining saliva. Administration should follow the prescriber’s instructions regarding timing and any fluid restrictions.

The most serious risks include severe hyponatremia, which can lead to seizures, cerebral edema, or coma, and water intoxication from excessive fluid retention. Rare but critical reactions such as anaphylaxis, thromboembolic events, marked hypotension, and cardiac arrhythmias may also occur. Patients should be monitored closely for signs of electrolyte imbalance.

Minirin Melt is contraindicated in patients with known hypersensitivity to desmopressin or any excipients, in those with uncontrolled hyponatremia, severe renal impairment, or chronic water intoxication. Caution is also advised for individuals with a history of epilepsy, heart failure, or uncontrolled hypertension, as these conditions may increase the risk of adverse effects.